High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201–995 (Sandostatin®) in Acromegaly
Acute and chronic studies have demonstrated the effectiveness of the long-acting somatostatin analogue SMS 201–995 (Sandostatin®) in the treatment of acromegaly. Daily doses of 100–300 µg Sandostatin given as multiple injections in most cases induce satisfactory suppression of GH release. No consistent shrinkage of the pituitary tumour has been demonstrated.
KeywordsGrowth Hormone Pituitary Tumour Growth Hormone Level Growth Hormone Response Growth Hormone Release
Unable to display preview. Download preview PDF.